Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells
about
New strategies in lung cancer: epigenetic therapy for non-small cell lung cancerRoles of Chk1 in cell biology and cancer therapyArsenic exposure and the induction of human cancersCDA: combinatorial drug discovery using transcriptional response modulesPanobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cellsA phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumorsHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction networkHistone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.Rational Combinations of Targeted Agents in AMLThe pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Epigenetic therapy in lung cancer.The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.Entinostat for treatment of solid tumors and hematologic malignancies.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.Epigenetics in lung cancer diagnosis and therapy.VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.Chaetocin induces endoplasmic reticulum stress response and leads to death receptor 5-dependent apoptosis in human non-small cell lung cancer cells.Biology and Management of Patients With Triple-Negative Breast Cancer.Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Zac1 is a histone acetylation-regulated NF-κB suppressor that mediates histone deacetylase inhibitor-induced apoptosis.Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G₂ delay and mitotic defects.Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells.
P2860
Q28236190-37A2AE20-9E14-4B9C-BD13-4C336C519BE4Q28289548-046A8F83-D355-4AF1-A771-A3EB8BFA36C8Q28394700-FCE3AD12-7982-4A17-9041-FEEA7D595CD0Q28482122-CFFA2791-D30C-418A-BB2A-643E97997D20Q28533896-1634796A-D8D2-4D10-BC7C-FD018E98F397Q33732128-9A0E8AC6-758F-478D-814E-8D5CB825A338Q33983255-8D40BB6E-A3D4-40A3-ADC7-DF05D3517670Q34468386-DADF579D-2FA5-4B09-867D-6DD404D8BAD8Q34541564-6B803C83-CE22-4D4E-B4CA-66E837EBCC74Q34808616-ECBC87AD-9EF8-4A13-AB78-67C0B282207EQ35287823-634F2A4E-1201-4230-ADE8-0F0B1ACF1119Q35750491-0D6B400C-6A12-452A-8180-2285814F6A4FQ35870933-0F925FBC-710D-45B6-A661-A075F0FF1D18Q36843733-0E76ABEB-DF5B-45B6-9F52-1276CB9E8BBAQ36876973-9F691A18-607D-4027-9311-E19D732E8BE5Q36885903-D4BDFBDA-714A-41A6-90D5-BFD44B82881DQ36927012-A83C5518-76C2-42CB-9864-608DA17B9013Q36946725-5EEAC9C1-3F42-4E5C-8600-0F61947DAEF4Q37701599-77113300-A0A7-45D7-ABEB-08F83C755973Q37925846-0A4A4EBE-DE00-4C81-815D-F5BFBD578B50Q38016227-98D6B7BA-C732-4589-A20C-86D468CCAA11Q38121995-BCCA83DF-B156-43B0-9782-E303C3A17581Q38457939-3A579693-8BDD-4A93-B71A-49855A8228FDQ38826861-7502A6D5-D3D1-4770-8451-11F486B40545Q38836957-3B935D10-9E85-4D88-9884-F813C3065FF1Q38893074-E38C172D-C095-41D3-B248-C147B32F6A60Q38948573-8AE7F1AD-399B-42AF-84AE-1281A40A8339Q38984578-7A72411B-59C7-409F-9EB3-2CE086269554Q39067523-51E2FEF0-A4AE-48F0-94F4-8200F7C13290Q39096970-9789BE2C-0651-4B50-AFCA-BDD2090DB042Q39123831-75363C51-CD57-4731-86C4-5D2120F2F5A7Q39248784-05A9E31A-7EA3-4F08-AA0E-895C041A0D6DQ39271550-27200C5A-34A1-48DD-8CB8-14B6FE4FEA7AQ39442905-6C1D491C-ADD9-485E-9361-C9374ACD85B8Q47136713-68862BB0-7A0E-47A2-AAFF-0D7593D9160E
P2860
Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Histone deacetylase inhibitors ...... n-small cell lung cancer cells
@ast
Histone deacetylase inhibitors ...... n-small cell lung cancer cells
@en
type
label
Histone deacetylase inhibitors ...... n-small cell lung cancer cells
@ast
Histone deacetylase inhibitors ...... n-small cell lung cancer cells
@en
prefLabel
Histone deacetylase inhibitors ...... n-small cell lung cancer cells
@ast
Histone deacetylase inhibitors ...... n-small cell lung cancer cells
@en
P2093
P2860
P1433
P1476
Histone deacetylase inhibitors ...... n-small cell lung cancer cells
@en
P2093
Eric Haura
Jennifer Gemmer
Jenny M Kreahling
Soner Altiok
W Douglas Cress
William Brazelle
P2860
P304
P356
10.1371/JOURNAL.PONE.0014335
P407
P577
2010-12-14T00:00:00Z